A5067126589- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Childhood Cancer Survivors' Quality of Life
- CAR-T cell therapy research
- Cardiac, Anesthesia and Surgical Outcomes
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- Neuroblastoma Research and Treatments
- Hemodynamic Monitoring and Therapy
- Immunodeficiency and Autoimmune Disorders
- Neutropenia and Cancer Infections
- Immunotherapy and Immune Responses
- Cancer therapeutics and mechanisms
- Acute Kidney Injury Research
- Hematological disorders and diagnostics
- Pharmaceutical studies and practices
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Sepsis Diagnosis and Treatment
- Cardiac Health and Mental Health
- Autoimmune and Inflammatory Disorders Research
- Aortic aneurysm repair treatments
Cincinnati Children's Hospital Medical Center
2016-2025
Children's Hospital Colorado
2024-2025
University of Cincinnati
2013-2025
University of Colorado Anschutz Medical Campus
1999-2025
University of Colorado Denver
2010-2025
Denver School of Nursing
2025
British Columbia Children's Hospital
2024
University of British Columbia
2024
University of Toronto
2024
Seattle Children's Hospital
2021-2024
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled < 18 years old BCP-ALL phase I dosage-escalation part II part, using 6-week treatment cycles. Primary end points were maximum-tolerated dosage (phase I)...
Although inotuzumab ozogamicin (InO) is recognized as an effective agent in relapsed acute lymphoblastic leukemia (ALL) adults, data on safety and efficacy pediatric patients are scarce. We report the use of InO 51 children with relapsed/refractory ALL treated compassionate program. In this heavily pretreated cohort, complete remission was achieved 67% overt marrow disease. The majority (71%) responders were negative for minimal residual Responses observed irrespective cytogenetic subtype or...
Children's Oncology Group trial AALL1621 was conducted to prospectively determine the safety and efficacy of inotuzumab ozogamicin (InO) in pediatric adolescent patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
Abstract Objectives/Hypothesis: To document the increasing incidence of oropharyngeal (OP) cancer and to provide evidence that this increase is caused by oncogenic human papilloma virus (HPV). Study Design: Epidemiologic review retrospective case series analysis. Methods: We collected data from Colorado United States comparing average annual age‐adjusted rates OP non‐OP head neck between periods 1980 1990 1991 2001. obtained on 72 patients with a single county in Colorado, through 2004. HPV...
S ummary . We report clinical, morphological and surface marker studies on seven patients with the common type of chronic lymphocytic leukaemia (CLL) whose disease underwent an insidious though progressive change in character increasing refractoriness to treatment. This transformation was accompanied by appearance a population immature‐appearing cells peripheral blood which resembled prolymphocytes, both at light electron microscopy. The characteristic feature presence two distinct...
Survivors of childhood Hodgkin's lymphoma (HL) are at risk for second malignant neoplasms (SMNs). It is theorized that this may be attenuated in patients treated with lower doses radiation. We report the first long-term outcomes a cohort pediatric survivors HL chemotherapy and low-dose radiation.Pediatric (n = 112) Stanford from 1970 to 1990 on two combined modality treatment protocols were identified. Treatment included six cycles 15 25.5 Gy involved-field radiation optional 10 boosts bulky...
Abstract Acute kidney injury due to high-dose methotrexate (HDMTX) is a serious, life-threatening toxicity that can occur in pediatric and adult patients. Glucarpidase treatment approved by the Food Drug Administration for high concentrations context of dysfunction, but guidelines when use it are unclear. An expert panel was convened provide specific, consensus glucarpidase patients who develop HDMTX-induced nephrotoxicity delayed excretion. The guideline provides recommendations identify...
Rearrangements of the mixed lineage leukemia (MLL) gene occur frequently in infants with both acute lymphoblastic (ALL) and myeloid (AML). Conversions cell are rare, but most commonly setting MLL‐rearrangement. Blinatumomab is a bidirectional antibody targeting CD19 significant activity relapsed B‐precursor ALL. We report an infant ALL t(4;11)(q21;q23) refractory to cytotoxic chemotherapy who was treated blinatumomab. Following rapid initial clearance peripheral lymphoblasts, bone marrow...
While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, following relapse poor. Previous studies suggest proteasome inhibition with chemotherapy improves ALL response rates. This phase 2 Children's Oncology Group study tested the hypothesis that adding inhibitor bortezomib to increases complete rates (CR2). Evaluable patients (n = 135, 103 B-ALL, 22 T-ALL, 10 T-lymphoblastic lymphoma) were treated reinduction plus bortezomib. Overall CR2 68 ± 5% for precursor B-ALL...
B-cell acute lymphoblastic leukemia (B-cell ALL) is the most common childhood cancer. Despite a high overall cure rate, relapsed ALL remains leading cause of cancer-related death among children. The addition bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by National Cancer Institute) in children may improve outcomes.
S ummary . The morphology of the cells from 29 cases T‐prolymphocytic leukaemia (T‐PLL) was studied by light (LM) and transmission electron microscopy (TEM) compared with that 3 B‐cell PLL. membrane phenotype T‐PLL T4 +, T8 ‐ in two‐thirds cases, others being T4‐ T8+ or T4+ T8+. Two morphological types were defined according to nuclear features: regular (55% cases) irregular (45% cases). a regular, round oval, outline resembled B‐PLL but had less abundant cytoplasm higher nucleo‐cytoplasmic...
Screening adolescents in emergency departments (EDs) for suicidal risk is a recommended strategy suicide prevention. Comparing screening measures on predictive validity could guide ED clinicians choosing tool.To compare the Ask Suicide-Screening Questions (ASQ) instrument with Computerized Adaptive Screen Suicidal Youth (CASSY) prediction of behavior among seen EDs, across demographic and clinical strata.The Emergency Department Study Teens at Risk Suicide prospective, random-series,...
A systematic analysis of the blast cell population was carried out on samples from 50 patients suffering transformation chronic granulocytic leukaemia (CGL) (31) and myelofibrosis (4), acute (AM) (11) undifferentiated (4). Transmission electron microscopy (TEM), used in 41 samples, included: morphology techniques for myeloperoxidase (MPO), platelet-peroxidase (PPO) acid phosphatase (AP). The majority cases were also studied by light cytochemistry with a battery markers which are reported...